Synovus Financial’s GSK GSK Stock Holding History

Synovus Financial’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	$5.93M	Sell	137,489 -56,536	-29%	-$2.21M	0.07%	172
2025 Q2	$7.45M	Buy	194,025 +52,998	+38%	+$2.03M	0.09%	141
2025 Q1	$5.46M	Sell	141,027 -28,055	-17%	-$1.03M	0.07%	166
2024 Q4	$5.72M	Sell	169,082 -7,719	-4%	-$278K	0.07%	163
2024 Q3	$7.23M	Sell	176,801 -46,216	-21%	-$1.89M	0.08%	151
2024 Q2	$8.59M	Buy	223,017 +55,004	+33%	+$2.31M	0.11%	118
2024 Q1	$7.2M	Buy	168,013 +30,957	+23%	+$1.28M	0.09%	128
2023 Q4	$5.08M	Sell	137,056 -736	-0.5%	-$26.4K	0.07%	162
2023 Q3	$5M	Buy	137,792 +11,551	+9%	+$410K	0.06%	187
2023 Q2	$4.5M	Buy	126,241 +4,272	+4%	+$153K	0.05%	204
2023 Q1	$4.34M	Buy	121,969 +12,827	+12%	+$449K	0.05%	211
2022 Q4	$3.84M	Buy	109,142 +23,137	+27%	+$771K	0.04%	219
2022 Q3	$2.53M	Buy	86,005 +12,918	+18%	+$490K	0.03%	280
2022 Q2	$3.97M	Buy	73,087 +2,526	+4%	+$139K	0.05%	207
2022 Q1	$3.84M	Sell	70,561 -4,119	-6%	-$224K	0.04%	222
2021 Q4	$4.11M	Buy	74,680 +1,326	+2%	+$69K	0.04%	229
2021 Q3	$3.5M	Buy	73,354 +11,688	+19%	+$587K	0.04%	226
2021 Q2	$3.07M	Sell	61,666 -316	-0.5%	-$15.2K	0.03%	243
2021 Q1	$2.76M	Buy	61,982 +45,759	+282%	+$2.08M	0.03%	231
2020 Q4	$745K	Buy	16,223 +2,333	+17%	+$107K	0.01%	450
2020 Q3	$655K	Sell	13,890 -443	-3%	-$22.2K	0.01%	431
2020 Q2	$731K	Sell	14,333 -17,549	-55%	-$900K	0.01%	383
2020 Q1	$1.51M	Buy	31,882 +18,704	+142%	+$998K	0.02%	307
2019 Q4	$773K	Buy	13,178 +107	+0.8%	+$5.95K	0.01%	382
2019 Q3	$696K	Buy	13,071 +534	+4%	+$27.5K	0.01%	394
2019 Q2	$626K	Sell	12,537 -647	-5%	-$32.5K	0.01%	419
2019 Q1	$689K	Buy	13,184 +18	+0.1%	+$899	0.01%	388
2018 Q4	$628K	Buy	13,166 +1,153	+10%	+$56.8K	0.01%	383
2018 Q3	$602K	Sell	12,013 -377	-3%	-$19.2K	0.01%	427
2018 Q2	$625K	Sell	12,390 -555	-4%	-$28K	0.01%	407
2018 Q1	$634K	Sell	12,945 -1,142	-8%	-$53.2K	0.01%	405
2017 Q4	$626K	Sell	14,087 -8,507	-38%	-$393K	0.01%	385
2017 Q3	$1.15M	Sell	22,594 -552	-2%	-$28K	0.02%	270
2017 Q2	$1.25M	Sell	23,146 -1,081	-4%	-$57.6K	0.03%	253
2017 Q1	$1.27M	Sell	24,227 -4,173	-15%	-$212K	0.03%	232
2016 Q4	$1.37M	Sell	28,400 -11,383	-29%	-$562K	0.03%	210
2016 Q3	$2.14M	Buy	39,783 +453	+1%	+$24.8K	0.05%	156
2016 Q2	$2.13M	Sell	39,330 -4,124	-9%	-$217K	0.05%	162
2016 Q1	$2.21M	Sell	43,454 -332	-0.8%	-$16.5K	0.05%	161
2015 Q4	$2.21M	Buy	43,786 +90	+0.2%	+$4.59K	0.05%	158
2015 Q3	$2.09M	Buy	43,696 +290	+0.7%	+$15.1K	0.06%	157
2015 Q2	$2.25M	Buy	43,406 +1,378	+3%	+$77.6K	0.06%	173
2015 Q1	$2.42M	Buy	42,028 +3,918	+10%	+$225K	0.06%	165
2014 Q4	$2.03M	Buy	38,110 +5,264	+16%	+$295K	0.05%	177
2014 Q3	$1.89M	Buy	32,846 +2,024	+7%	+$124K	0.05%	171
2014 Q2	$2.06M	Buy	30,822 +1,805	+6%	+$122K	0.06%	157
2014 Q1	$1.94M	Buy	29,017 +549	+2%	+$37.1K	0.06%	160
2013 Q4	$1.89M	Sell	28,468 -1,290	-4%	-$83.6K	0.05%	164
2013 Q3	$1.87M	Sell	29,758 -240	-0.8%	-$15.4K	0.06%	151
2013 Q2	$1.87M	Buy	+29,998	New	+$1.9M	0.06%	181

Other funds holding GSK

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

JEST

JTC Employer Solutions Trustee St Helier, Jersey $1.2B AUM 37.55% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Synovus Financial's GSK Position: Q3 2025 in Review

Synovus Financial reduced its GSK (GSK) stake by 29% in Q3 2025, selling an estimated $2.21M and leaving 137,489 shares worth $5.93M. The position accounts for 0.07% of the portfolio, ranked #172.

Synovus Financial first reported a position in GSK in Q2 2013 and has held it in 50 quarters since. The position peaked at $8.59M in Q2 2024. 895 funds tracked by Wall St. Rank hold GSK as of Q3 2025.

Synovus Financial held 137,489 shares of GSK worth $5.93M as of Q3 2025.
Synovus Financial sold 56,536 GSK shares in Q3 2025, an estimated $2.21M.
GSK made up 0.07% of Synovus Financial's portfolio in Q3 2025, its #172 holding.
Synovus Financial first reported a position in GSK in Q2 2013 and has held it in 50 quarters since.
Synovus Financial's GSK position peaked at $8.59M in Q2 2024.
895 funds tracked by Wall St. Rank held GSK as of Q3 2025.

Based on Synovus Financial's 13F filing for Q3 2025, filed 7 Nov 2025.